Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
Marco Di Nicola, Maria Pepe, Silvia Montanari, et al.
European Neuropsychopharmacology (2023) Vol. 70, pp. 21-28
Open Access | Times Cited: 18

Showing 18 citing articles:

Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial
Roger S. McIntyre, Lee Phan, Angela T.H. Kwan, et al.
Brain (2023) Vol. 147, Iss. 3, pp. 849-857
Closed Access | Times Cited: 28
Understanding Pediatric Bipolar Disorder Through the Investigation of Clinical, Neuroanatomic, Neurophysiological and Neurocognitive Dimensions: A Pilot Study
Alessio Simonetti, Evelina Bernardi, Sherin Kurian, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 152-152
Open Access
Decreased neutrophil-to-lymphocyte ratio predicted cognitive improvement in late-life depression treated with vortioxetine: Findings from an eight-week randomized controlled trial
Lingfeng Xue, E. Thomas Lewis, Mariia Bocharova, et al.
Brain Behavior and Immunity (2025)
Open Access
Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
Angela T.H. Kwan, Ziji Guo, Felicia Ceban, et al.
Advances in Therapy (2024) Vol. 41, Iss. 5, pp. 1983-1994
Closed Access | Times Cited: 3
Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition
Jennifer Frontera, Alla Guekht, Ricardo Allegri, et al.
Journal of the Neurological Sciences (2023) Vol. 454, pp. 120827-120827
Closed Access | Times Cited: 9
Washed microbiota transplantation targeting both gastrointestinal and extraintestinal symptoms in patients with irritable bowel syndrome
Zulun Zhang, Qianqian Li, Sheng Zhang, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023) Vol. 127, pp. 110839-110839
Closed Access | Times Cited: 8
Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
Sebastian Badulescu, Gia Han Le, Sabrina Wong, et al.
Neurological Sciences (2024) Vol. 45, Iss. 4, pp. 1335-1342
Closed Access | Times Cited: 2
The effectiveness and tolerability of agomelatine in the treatment of depression after COVID-19 infection in Russian daily clinical practice (TELESPHOR study)
В Э Медведев, А Н Боголепова, Denis P. Morozov, et al.
Authorea (Authorea) (2024)
Open Access | Times Cited: 1
Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine
Alessandro Cuomo, Andrea Aguglia, Domenico De Berardis, et al.
Annals of General Psychiatry (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study
Marco Di Nicola, Michael Adair, Andreas Rieckmann, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 7, pp. 615-623
Open Access | Times Cited: 1
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update
Udo Bonnet, Georg Juckel
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 1
Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
Gia Han Le, Angela T.H. Kwan, Sabrina Wong, et al.
Advances in Therapy (2023) Vol. 41, Iss. 2, pp. 686-695
Closed Access | Times Cited: 3
Physical and cognitive correlates, inflammatory levels, and treatment response in post-COVID-19 first-onset vs. recurrent depressive episodes
Marco Di Nicola, Maria Pepe, Lorenzo De Mori, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 274, Iss. 3, pp. 583-593
Open Access | Times Cited: 2
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 531-531
Open Access
Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder
Alessandro Cuomo, G. Barillà, M. Cattolico, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 5, pp. 465-476
Closed Access
European and US Aeromedical Authority Guidance for Neurocognitive Evaluation of Airline Pilots With Mental Disorders
Alpo Vuorio, Anna-Stina Suhonen-Malm, Bruce Budowle, et al.
Aviation Psychology and Applied Human Factors (2024) Vol. 14, Iss. 1, pp. 58-69
Closed Access
Antidepressant and anxiolytic efficacy and tolerability of agomelatine in the treatment of depression after COVID-19 in daily clinical practice (non-interventional study TELESPHOR)
Константин Быков, А Н Боголепова, Denis P. Morozov, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 6, pp. 61-70
Open Access
EXPLORING THE EFFICACY OF PSYCHOTROPIC DRUG COMBINATIONS FOR COVID-19 DEPRESSION
Bruna Evandra Resende Silva, Jardison Rocha Silva, Rodrigo Cé
Revista Multidisciplinar em Saúde (2023) Vol. 4, Iss. 3, pp. 01-16
Open Access
Page 1

Scroll to top